Cerebral Venous Thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Dias, L (Author) Other; Ricardo Soares dos Reis (Author) FMUP; Meira, J (Author) Other; Ferrao, D (Author) Other; Soares, PR (Author) Other; Pastor, A (Author) Other; Gama, G (Author) Other; Fonseca, L (Author) FMUP; Fagundes, V (Author) Other; Marta Carvalho (Author) FMUP

Journal

Title: Journal of Stroke and Cerebrovascular Diseases

Vol. 30

ISSN: 1052-3057

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 30 Citations

Scopus - 37 Citations

Other information

Authenticus ID: P-00V-4XP

DOI: 10.1016/j.jstrokecerebrovasdis.2021.105906

Abstract (EN): The development of SARS-CoV-2 vaccines has raised several concerns regarding venous thromboembolism, namely cerebral venous thrombosis. Although cerebral venous thrombosis has been reported after administration of a viral vector vaccine, due to a possible auto-immune mechanism inducing thrombocytopenia, the same has not happened in mRNA vaccines. We report two cases of cerebral venous thrombosis, shortly after administration of mRNA vaccine. In both patients, there was no evidence of thrombocytopenia or anti platelet antibodies, and alternative causes for cerebral venous thrombosis were found. As such, despite the temporal relation of both cases to vaccine administration, these types of cerebral venous thrombosis do not seem to be pathophysiological different from cerebral venous thrombosis not associated to SARS-CoV-2 vaccination. Continuous pharmacovigilance is necessary to monitor possible new events and clarify this association.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 3